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Abstract
Background: While hyperglycemia-induced oxidative stress damages peripheral neurons, technical limitations have, in part,
prevented in vivo studies to determine the effect of hyperglycemia on the neurons in the central nervous system (CNS).
While olfactory dysfunction is indicated in diabetes, the effect of hyperglycemia on olfactory receptor neurons (ORNs)
remains unknown. In this study, we utilized manganese enhanced MRI (MEMRI) to assess the impact of hyperglycemia on
axonal transport rates in ORNs. We hypothesize that (i) hyperglycemia induces oxidative stress and is associated with
reduced axonal transport rates in the ORNs and (ii) hyperglycemia-induced oxidative stress activates the p38 MAPK pathway
in association with phosphorylation of tau protein leading to the axonal transport deficits.
Research Design and Methods: T1-weighted MEMRI imaging was used to determine axonal transport rates post-streptozotocin
injection in wildtype (WT) and superoxide dismutase 2 (SOD2) overexpressing C57Bl/6 mice. SOD2 overexpression reduces
mitochondrial superoxide load. Dihydroethidium staining was used to quantify the reactive oxygen species (ROS), specifically,
superoxide (SO). Protein and gene expression levels were determined using western blotting and Q-PCR analysis, respectively.
Results: STZ-treated WT mice exhibited significantly reduced axonal transport rates and significantly higher levels of ROS,
phosphorylated p38 MAPK and tau protein as compared to the WT vehicle treated controls and STZ-treated SOD2 mice. The
gene expression levels of p38 MAPK and tau remained unchanged.
Conclusion: Increased oxidative stress in STZ-treated WT hyperglycemic mice activates the p38 MAPK pathway in
association with phosphorylation of tau and attenuates axonal transport rates in the olfactory system. In STZ-treated SOD-
overexpressing hyperglycemic mice in which superoxide levels are reduced, these deficits are reversed.
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Introduction
Diabetes affects more than 300 million people worldwide [1].
While the effect of hyperglycemia has been well characterized in
peripheral neurons, we know little about the effect of hyperglycemia
on the central nervous system (CNS) partly due to the limitation of
noninvasive dynamic imaging techniques to assess neuronal
function [2]. Even though olfactory dysfunction is indicated during
diabetes, little is known about the effect of hyperglycemia on the
olfactory system. [3–5]. We previously described measurement of
axonal transport rates in the olfactory bulbs in a mouse model of
Alzheimer’s disease [6,7]. In this study, we utilized manganese
enhanced MRI (MEMRI) to determine the effect of short-term
hyperglycemia-induced oxidative stress on axonal transport rates in
the olfactory receptor neurons (ORNs) in mice.
Oxidative stress is regulated by the levels of reactive oxygen
species (ROS), which includes superoxides, hydroxyl radical, and
hydrogen peroxide. Normally, ROS produced during cellular
respiration are removed by mitochondrial antioxidant enzymes
such as superoxide dismutase 2 (SOD2), which converts
superoxide to hydrogen peroxide, which in turn is converted to
water and oxygen by glutathione, and catalase. During hypergly-
cemia, excess glucose levels induce over-production of ROS in the
mitochondria, which subsequently causes depletion of SOD2 and
leads to cellular injury [2,8–10].
Whereas hyperglycemia-induced oxidative stress damages
peripheral neurons, overexpression of SOD2 reduces the super-
oxide load and prevents hyperglycemia-induced cellular injury in
dorsal root ganglia (DRG) cultures [10]. Additionally, overexpres-
sion of SOD2 reduces symptoms of neuropathy in streptozotocin
(STZ) treated C57Bl/6 mice [10]. Furthermore, the mechanism of
neuronal injury due to hyperglycemia-induced oxidative stress has
been shown to occur through the activation of p38 mitogen-
activated protein kinases (MAPK) [9]. Activation of the p38
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13463MAPK signaling cascade is associated with cellular response to
cytokines, irradiation, and oxidants [11–13]. In peripheral
neurons, hyperglycemia-induced activation of p38 MAPK path-
way is associated with reduced motor nerve conduction velocity
[11] and apoptosis [14].
We hypothesize that (i) hyperglycemia induces oxidative stress
and is associated with reduced axonal transport rates in the CNS.
We also hypothesize that hyperglycemia-induced oxidative stress
activates the p38 MAPK pathway in association with phosphor-
ylation of tau protein leading to axonal transport deficits in CNS
neurons. Last, we hypothesize that reduction of oxidative stress
through the overexpression of SOD2 should ameliorate these
effects.
To address these hypotheses, we utilized a dynamic, in vivo, MRI
methodology, MEMRI, to measure axonal transport rates non-
invasively [6,7]. Manganese ion (Mn
2+) is a paramagnetic MRI
contrast agent that instills positive contrast in spin-lattice (T1)
weighted MRI images [15]. Additionally, Mn
2+ is known to enter
the cells via voltage-gated calcium channels [16]. Once in the cells,
Mn
2+ is packaged into vesicles and transported along microtubules
via fast axonal transport and released at the synapse [6–7,17–22].
The rates of Mn
2+ transported along the axons are reflective of the
fast axonal transport rates [6–7,17–22]. Dynamic T1-weighted
MEMRI enables trans-synaptic, in vivo, MRI detectable neuronal
tract tracing to map neuronal pathways [6–7,17–22].
In this study, we utilized two different animal models: (i) STZ-
induced hyperglycemia mice and (ii) a heterozygotic SOD2
overexpressing STZ-treated hyperglycemia mice. Overexpression
of SOD2 reduces superoxide load in DRG neurons [10] and in
hippocampal neurons [23] and prevents cellular injury. The
SOD2 overexpressing mice are a transgenic line that overexpress
human SOD2 gene driven by the b-actin promoter [24]. We first
determined axonal transport rates in STZ-treated wildtype (WT)
and SOD2 overexpressing mice. We next determined the levels of
ROS in the different groups of mice. Last, we determined the
protein and gene expression levels of p38 MAPK and tau. Our
findings suggest that hyperglycemia-induced oxidative stress instills
axonal transport deficits in ORNs through the phosphorylation of
p38 MAPK and tau.
Methods
Animal Models, MRI Imaging and Processing
Two to four month-old WT and SOD2 overexpressing mice on
a C57Bl/6 background were utilized for this study. STZ treatment:
Hyperglycemia was induced by an intraperitoneal (i.p.) injection of
170 mg/g of STZ. Control animals received vehicle injections of
0.01 M sodium citrate. Mice with fasting blood glucose levels
.200 mg/dl or non-fasting blood sugar .250 mg/dl (on the third
day post-STZ treatment), were considered hyperglycemic. Exper-
iments were performed 1-week post-injections. Insulin treatment:I n
order to first validate the effect of STZ-induced hyperglycemia
and to rule out possible effects of STZ-toxicity on the axonal
transport rates we treated the hyperglycemic mice with insulin.
Linbit insulin implants were utilized for the insulin treatment.
(LinShin, Inc, Canada). After confirmation of high glucose in STZ
treated animals used, half of a Linbit tablet was implanted
subcutaneously on the back of the mice. The feeding glucose levels
were checked twice during the following week. If the glucose levels
were over 250 mg/dl, an additional half tablet of insulin was
implanted. Glucose treatment: To validate that the changes in axonal
transport rates were from increased glucose levels, chronic
hyperglycemia was induced by injecting 25% D-glucose (i.p.) 4
times a day for 5 days and a single injection on the sixth day before
imaging at a dose of 1.25 g/kg mouse. All mice were housed at
Baylor College of Medicine’s transgenic mouse facility in
compliance with the National Institutes of Health (NIH) guidelines
for Care and Use of Laboratory Animals. The mouse facility is
kept on a 12-hour light–dark cycle, with a regular feeding and
cage-cleaning schedule. All experiments were approved and
conducted in compliance with BCM’s Institutional Animal Care
and Use (IACUC) regulations under animal protocol #AN-3334.
Mn
2+ administration was conducted as we have previously
performed [6–7,17]. Briefly, animals were anesthetized with 5%
isoflurane. Anesthetized mice were nasally lavaged with 4 mlo f
0.75 mg/ml MnCl2 dissolved in nanopure water. The olfactory
system is easily accessible and minimally invasive. Following Mn
2+
administration, the animals were allowed to recover. One hour
post-lavage, animals were re-anesthetized with 5% isoflurane and
imaged. The body temperature was maintained at 37u utilizing a
heated air system (SA Instruments, Inc, Stony Brook, NY) and
maintained under anesthesia with 2% isoflurane in 100% O2. The
respiration was monitored with a pressure pad placed under the
animal and temperature was monitored by a rectal probe (SA
Instruments, Inc, Stony Brook, NY). Respiratory rates and
temperature were monitored using the Model 1025 Small Animal
Monitoring and Gating System software (SA Instruments, Inc,
Stony Brook, NY).
A series of T1-weighted images were acquired utilizing a 9.4T,
Bruker Avance Biospec Spectrometer, 21 cm bore horizontal
scanner with a 35 mm volume resonator (Bruker BioSpin,
Billerica, MA). The imaging parameters to acquire spin-echo 2D
images were as follows: repetition time, (TR) =400 ms; echo time
(TE) =10.2 ms; FOV=3.0 cm; slice thickness = 1 mm; matrix
dimensions =1286128; number of averages, NA=2; and number
of cycles =15; each cycle took approximately 2 min 8 sec to
acquire using Paravision software (Bruker BioSpin, Billerica, MA).
Core temperature was maintained at 37uC during scanning.
Regions of interest (ROI) were localized on axial slice. The axial
slice location was similar between all the mice and was consistently
located 1 mm in front of the posterior of the olfactory bulb (OB).
For the initial axonal transport studies (Figure 1A), wildtype (WT),
N=3; WT treated with STZ (WT-STZ) with glucose levels =
200–299, N=3; for WT-STZ with glucose levels =.300, N=5.
For the axonal transport studies in which insulin was administered
(Figure 1B), WT, N=3; WT-STZ, N=3; WT-STZ treated with
an insulin pellet. N=4. For the chronic hyperglycemia studies
(Figure 1C), WT, N=4; WT + glucose, N=5. For the SOD-2
experiments, WT, N=12; WT-STZ, N=4; SOD-2 overexpress-
ing animals (SOD-2), N=4; SOD-2 treated with STZ (SOD2-
STZ), N=4.
Signal intensities at the ROI were normalized to un-enhanced
muscle from the same slice. The ROI was identified as we have
previously performed [6,7]. Briefly, the ROI was identified by
locating the midpoint of the length of the OB and then extending a
perpendicular line from the midpoint out to the olfactory neuronal
layer. The normalized signal intensity was plotted versus time. The
slope of the best fit linear regression curve indicated the rate of
axonally transported Mn
2+.
Histology and Biochemistry
Dihydroethidium (DHE) was obtained from Invitrogen (Carls-
bad, CA). Animals were treated with a single i.p. injection of
27 mg/kg of DHE. At 24 hours, DHE-injected animals were
cardiac-perfused with 4% paraformaldehyde, the mice heads were
decalcified with 0.24 M ethylenediaminetetraacetic acid for 8–10
days. The heads were then sectioned on a cryostat and mounted
with Vectashield H1200 containing DAPI (Vector Laboratories,
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cence (Excitation- 488 nm, Emission 590 nm, exposure time
100 ms) and DAPI (Excitation 405 nm, Emission 420–480 nm,
exposure time 20 ms) using a Zeiss fluorescence microscope.
Ethidium fluorescence (indicative of superoxide levels) was
quantified in the nasal epithelium with the NIH software, ImageJ
(Bethesda, Madison). We determined the ethidium fluorescence
intensity using a 50650 pixels square ROI identified on
130061030 pixels, RGB, 406 magnification images of nasal
cavity sections and normalized the DHE mean signal intensity to
the corresponding DAPI intensity. Five ROIs per section and 1–4
sections per animal were analyzed. Sections were randomly
selected from the area spanning the depth of the nasal cavity. WT,
N=4, WT-STZ, N=6; SOD2, N=4; SOD-STZ, N=4.
The OBs from mice brains were dissected fresh on ice and
homogenized in lysis buffer (137 mM NaCl, 20 mM Tris-Base
pH 7.6, 5 mM EDTA, 50 mM NaF, 2 mM NaVO4,1 m M
PMSF, and protease and phosphatase inhibitor cocktails from
Sigma–Aldrich) using a sonic dismembrator (Fisher Scientific,
Waltham, MA). The homogenates were then centrifuged at
10,000 g for 5 minutes and supernatant was used to assay for
phosphorylated and total p38 MAPK and tau proteins. Total
protein from the supernatant was measured using a Bradford assay
(Bio-Rad, Hercules, CA). Proteins were equally loaded in each
well of 10% polyacrylamide gel and separated by SDS/PAGE and
then transferred onto a nitrocellulose membrane (Bio-Rad,
Hercules, CA). The membranes were blocked with 5% milk and
probed with 1:1000 dilution, anti-phospho-p38 MAPK, anti-p38
MAPK (Cell Signaling, Danvers, MA), anti-phospho-Tau (threo-
nine 205, serine 202) (MILLIPORE, Bellerica, MA), 1:10,000
dilution, anti-Tau (DAKO, Denmark), 1:30,000 dilution anti-a-
tubulin (Sigma), and 1:10,000 anti-b-actin antibodies (Sigma-
Aldrich, St. Louis, MO). Membranes were next incubated with
near-infrared fluorescent secondary antibodies from LI-COR
(Lincoln, NE) (anti-rabbit for phospho and total p38 MAPK and
Tau proteins and anti-mouse for a-tubulin and b-actin). Bands
were visualized using LI-COR Odyssey machine. Anisomycin
treated C6 cell extracts (Cell Signaling, Danvers, MA) were used as
a positive control for phosphorylated p38 MAPK protein analysis.
Brain homogenate from tau knockout mouse was used as a
negative control for phosphorylated Tau protein assays. Given the
multiple bands appearing on the p38 immunoblots, the specific
band corresponding to phospho-p38 was identified by comparison
to the positive control. Phospho-p38 yielded a double band at
around 38KD, both of which were analyzed for densitometry and
reported as a bar graph. For the western blot analysis of p38, WT,
N=7; WT-STZ, N=5; SOD2, N=5; SOD2-STZ, N=5. For the
total p38 protein levels, WT, N=7; WT-STZ, N=7; SOD2,
N=6; SOD2-STZ, N=5. For the western blot analysis of tau,
WT, N=7; WT-STZ, N=5; SOD2, N=5; SOD2-STZ, N=5.
Frozen brain samples were placed into TRI Reagent (Ambion,
Austin, TX) and quickly homogenized in a dounce tissue
homogenizer. RNA was isolated using the RiboPure kit (Ambion)
per manufacturer’s instructions. RNA quality was verified by
Figure 1. STZ-induced hyperglycemia impairs axonal transport in the olfactory receptor neurons. (A) Graph depicts axonal transport
rates (depicted as Mn
2+ DSI/t on Y axis, where ‘‘SI’’ is signal intensity and ‘‘t’’ is time) of Mn
2+at 1 week post-STZ treatment for WT(n=3) and WT-STZ
with fasting glucose levels 200–399 mg/dl (n=3), and .400 mg/dl (n=5). (B) Graph depicts the changes in axonal transport rates for WT (n=4), WT-
STZ (n=3), and WT-STZ+insulin treated mice (n=4). (C) The graph represents changes in axonal transport rates in a mouse model of WT-STZ (n=5) as
compared to WT mice (n=4). Statistical analysis: One way ANOVA, Tukey’s post test for more than 2 groups and Students t test to compare 2 groups.
*p ,0.05, ** p,0.01, *** p,0.001/WT = wildtype control. WT-STZ = Wildtype treated with streptozotocin.
doi:10.1371/journal.pone.0013463.g001
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RNA on denaturing agarose gel and ensuring an approximate 2:1
intensity ratio between 28S and 18S bands. RNA concentration
was determined via absorption of ultraviolet light at 260 nm in a
DU530 spectrophotometer (Beckman, Brea, CA). Total RNA
mass was normalized across samples for the cDNA synthesis
reaction. cDNA was synthesized using oligo-dT primers and
SuperScriptII reverse transcriptase (Invitrogen) per manufacturer’s
instructions. cDNA from the synthesis reaction was subjected to
quantitative, real-time PCR with SYBR Green reporter (Bio-Rad)
in the Mx3000P thermal cycler (Stratagene, La Jolla, CA). Cycle
threshold values were obtained by normalization to ROX
(Stratagene) reference dye. Transcripts were quantified by the D-
DCt method, normalizing to elongation factor EEF1G. Following
the reaction, product dissociation curves were analyzed to ensure
accurate readings. Primer sequences were: Tau forward (F):
GTGGAGGCAGTGTGCAAATA; Tau reverse (R): GCCAA-
TCTTCGACTGGACTC; p38MAPK F: TGAACTTCGCAA-
ATGTATTTATTGGT; p38MAPK R: ATCTGAGTCCAAA-
ACGAGCATCT; EEF1G F: GGCCAAACCAACCGCACC;
EEF1G R: CGATGTCACTGTCAGCAAAG. N=6 for all
groups of mice.
Data Analysis
Data are presented as mean +/- SEM. Statistical analyses
between 2 groups were performed by using a two-tailed student’s t
test, whereas comparisons involving multiple groups were
performed with a one-way ANOVA followed by Tukey’s or
Dunnett’s post test for multiple comparisons. P values #0.05 were
considered statistically significant. GraphPad Prism Software
(SanDiego, CA) was utilized for the analysis.
Results
First, we utilized MEMRI to determine axonal transport rates in
wildtype control (WT) and WT mice at 1 week post-STZ (WT-
STZ). The WT-STZ treated mice exhibited significant decreases
in axonal transport rates as compared to the WT, Figure 1A. In
order to confirm that the deficits in the axonal transport rates were
due to STZ-induced hyperglycemia and not STZ-induced toxicity,
we treated the mice with insulin pellets. Following 10 days of
insulin treatment the mice had an average non-fasting glucose
level of ,200 mg/dl. The STZ plus insulin treated mice displayed
significant recovery in the axonal transport rates, Figure 1B. In
addition, we measured axonal transport rates in a mouse model of
chronic hyperglycemia. The results indicated a significant
reduction in axonal transport rates in mouse model of chronic
hyperglycemia (fasting glucose levels 200–550 mg/dl) as compared
to the healthy controls (fasting glucose levels ,200 mg/dl)
Figure 1C. Taken together, the data demonstrated that the
deficits in axonal transport rates were due to hyperglycemia in
STZ treated mice.
To determine if axonal transport deficits were associated with
hyperglycemia-induced oxidative stress, we measured axonal
transport rates with MEMRI in STZ-treated SOD2 overexpress-
ing mice (SOD2-STZ). At 1 week post-STZ treatment, the
measured glucose levels of SOD2-STZ, WT-STZ, WT, and
SOD2 mice ranged from 283–598 mg/dl, 256–600 mg/dl, 143–
177 mg/dl, and 172–189 mg/dl. Figure 2A depicts pseudo
colored images (for ease of visualization and qualitative interpre-
tation) and Figure 2B depicts the corresponding grayscale image of
the olfactory bulbs of mice. The ROI at the outer layer of the
olfactory bulb is indicated by a circle and arrow. At the beginning
of the imaging session we observed little Mn
2+ signal intensity at
the ROI (depicted as light green in the ROI, Figure 2A, top row, 2
minute time point). By the end of the imaging session, at 32
minutes, the MRI signal intensity increased for vehicle-treated
WT and SOD2 mice as well as for the SOD2-STZ mice (depicted
by an increase in yellow color, Figure 2A, bottom row, 32 minute
time point) but remained relatively unchanged for the WT-STZ
mice as depicted by the light green color at the 32 minute time
point. Upon quantification of the Mn
2+ signal intensity we
observed that despite STZ-induced hyperglycemia, axonal trans-
port rates recovered significantly in SOD2 overexpressing mice as
opposed to the WT-STZ mice and were indistinguishable from
WT and SOD2 controls, Figure 2 C. To determine the association
of oxidative stress and axonal transport rates, we utilized
dihydroethidium (DHE) staining to measure the levels of ROS
in WT, SOD2, SOD2-STZ, and WT-STZ mice. Figure 3A
depicts 20 mm thick nasal cavity tissue sections. The first column
represents DHE fluorescent images which reflect ROS levels. The
second column depicts the corresponding DAPI images and the
third column represents an overlay of DHE and DAPI images.
The DHE fluorescent section from WT-STZ mice depicted
remarkably bright red fluorescence that signified probably high
levels of ROS as compared to the WT, SOD2, and SOD2-STZ
mice. Image analysis at the ROIs demonstrated that ROS levels
are significantly increased in hyperglycemic mice as compared to
the controls and that these levels normalized back to control levels
in STZ-treated SOD2 overexpressing mice, Figure 3B.
We next determined if the p38 MAPK pathway was affected in
STZ treated mice in association with the oxidative stress. Western
blotting analysis demonstrates significant increases in the levels of
phosphorylated p38 MAPK in WT-STZ mice as compared to the
WT, SOD2 and SOD2-STZ mice, Figure 4A. The levels of total
p38 MAPK protein, however, did not significantly differ in the
four groups of mice, Figure 4B. In addition, the p38 MAPK
mRNA levels also remained unchanged in all groups of mice,
Figure 4C. The phosphorylated and total p38 MAPK protein
levels from each sample were normalized to their respective a-
tubulin protein amounts; the western blots are shown in Figure 4D.
Taken together, the data indicate that phosphorylated p38 MAPK
levels increase in association with ROS in hyperglycemic mice
with increased oxidative stress and return to wildtype levels in
SOD2-STZ mice that have reduced superoxide load despite
hyperglycemia.
We also assessed the phosphorylation levels of tau at the
threonine-205 site. We observed that in WT-STZ mice, there was
an increase in the phosphorylation which returned to baseline levels
in SOD-STZ animals, Figure 5A. The total tau protein levels and
mRNA levels remained unchanged, Figure 5B and Figure 5C
respectively. The western blots results were normalized to b-actin
withtheblotsrepresentedinFigure5D.Together,thedataindicates
that significantly higher levels of site-specific phosphorylation of tau
in conjunction with activation of p38 MAPK occur in hyperglyce-
mic mice (WT-STZ) that have increased superoxide load as
compared to the WT, SOD2, and SOD2-STZ mice that have
reduced mitochondrial oxidative stress.
Discussion
The effects of hyperglycemia on the CNS remain poorly
understood. Our results indicate that MEMRI noninvasively
depicts significant reduction of axonal transport rates in WT-STZ
mice during hyperglycemia. Interestingly, the axonal transport
rates did not appear to be a function of the levels of hyperglycemia
as mice within the range of 200–300 mg/dl or .400 mg/dl
exhibited similar decreases in axonal transport as compared to
Transport in Hyperglycemia
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could potentially be explained by the fact that although ROS are
constantly produced in normal physiology, once a certain
threshold of ROS is reached, they become detrimental.
We also determined that the axonal transport rate deficits are
associated with activation of p38 MAPK signaling cascade and tau
phosphorylation in hyperglycemic mice at 1-week. One possible
explanation of these data include a perturbation in calcium (Ca
2+)
homeostasis as Mn
2+, which is used as a molecular MRI contrast
agent, is a Ca
2+ analogue [16]. Wseveral reports indicated that
calcium homeostasis is disturbed with increased levels of intracel-
lular calcium in several cells during long-term diabetes [25–26] and
increase in T-type calcium currents in peripheral neurons following
two weeks of hyperglycemia [27], 5-12 days of hyperglycemia does
not cause remarkable alterations in calcium homeostasis [25]. In
this work, we performed the MEMRI studies at 1 week post STZ-
treatment. which negates the effect of hyperglycemia on possible
differential uptake of Mn
2+ ions by neurons due to altered calcium
homeostasis and that our measurements are reflective of the axonal
transportofMn
2+as weandothershaveperformedandvalidatedin
the past [6–7,18–19].
Upon SOD2 overexpression, the deficits in axonal transport
recovered in association with restoration of levels of phosphor-
ylated p38 MAPK and tau protein. Because SOD2 is exclusively
localized to the mitochondria of SOD2 transgenic mice [28], our
data is indicative of the critical role that mitochondrial oxidative
stress plays during hyperglycemia as mitochondrial oxidative
stress has been implicated in diabetic associated pathologies. For
example, SOD2 overexpression in primary dorsal root ganglion
cultures or in mice protected cellular injury and prevented
development of signs of diabetic neuropathy (DN) respectively
[10]. Recently, Munusamy and Mac-Millan-Crow [29] reported
that overexpression of SOD2 prevented early stage hyperglyce-
mia-induced mitochondrial injury in normal renal rat proximal
tubular cells. Furthermore, overexpression of SOD2 significant-
ly prevented the development of retinopathy in mice by
preventing retina from diabetes-induced oxidative damage
[30]. Similarly, SOD2 overexpression in heart mitochondria
improved mitochondrial respiration, protected heart morphol-
ogy, and restored cardiac contractility of a diabetic heart [31].
Collectively, the data suggest that hyperglycemia-induced
mitochondrial oxidative stress is a major trigger of diabetes-
Figure 2. MEMRI experiments demonstrate that the axonal transport deficits in WT-STZ mice recover in SOD2-STZ mice. (A) Pseudo-
color MRI images depicting changes in Mn
2+ signal intensities (yellow color) at the beginning (2minutes) and at the end of the imaging session (32
minutes) at a region of interest (ROI) identified as a circle on the outer olfactory neuronal layer (ONL). Note that the WT, SOD and SOD2-STZ mice
exhibit a change from green (2 minute time point) to yellow (32 minute time point) whereas the WT-STZ animals exhibit a light green color at both
time points indicating that Mn
2+ has not traveled to these areas at the same rate. (B) Gray-Scale Image of the same data set in (A). (C) The graph
depicts normalized axonal transport rates (% control) in the WT and SOD2 mice treated with vehicle or STZ for a week before in vivo axonal transport
studies. Twelve mice were used in the WT group and four mice were used in each of WT-STZ, SOD2, and SOD2-STZ groups. Statistical analysis: One
way ANOVA, Dunnett’s post-test. * p,0.05. SOD2 = SOD-2 overexpressing mice; SOD2-STZ = SOD-2 overexpressing mice treated with STZ.
doi:10.1371/journal.pone.0013463.g002
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sections showing genotypic differences in DHE fluorescence. (B) The graph depicts ratio of DHE and corresponding DAPI fluorescence, which was
measured with ImageJ software. Significance was assessed by one way ANOVA with Dunnett’s post-test. For WT, WT-STZ, SOD2, and SOD2-STZ n=4,
6, 4, 4 respectively. ** p,0.01, * p,0.05 Bar=20 mm.
doi:10.1371/journal.pone.0013463.g003
Figure 4. Phosphorylated p38 MAPK significantly increase in WT-STZ mice and recovers in SOD2-STZ mice. Western blotting analysis
of OB tissues from WT, WT-STZ, SOD2, SOD2-STZ mice show: (A) changes in phosphorylated p38 MAPK levels (for WT n=7 and for WT-STZ, SOD2, and
SOD2-STZ n=5), (B) changes in total p38 MAPK protein levels, (for WT and WT-STZ n=7, for SOD2 n=6, and for SOD2-STZ n=5) (C) QPCR experiment
using brain homogenates depict relative changes in mRNA levels of p38 MAPK, six mice in each group and (D) representative western blot from OBs
homogenates from 1 week vehicle or STZ treated 2-4-month-old mice. The results are normalized to a-tubulin. Statistical analysis: One way ANOVA
followed by Dunnett’s post test. ** p,0.01, *p,0.05.
doi:10.1371/journal.pone.0013463.g004
Transport in Hyperglycemia
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SOD2 activity.
Our data also depicts hyperglycemia-induced oxidative stress
induces activation of p38 MAPK within 1-week of STZ treatment
of mice. Previous reports also demonstrate that hyperglycemia-
induced oxidative stress causes p38MAPK activation in peripheral
neuronal cultures after 16 h of exposure to high glucose, after
STZ-treated diabetic rats with 12 weeks of high glucose, and in the
sural nerves of type 1 and 2 diabetic patients [11,12]. We observe
that the increased phosphorylation of p38 MAPK in WT-STZ
mice is ameliorated in SOD2-overexpressing mice despite the
presence of hyperglycemia. Our WB data did not exhibit any
alteration in the level of p38 MAPK protein itself. The p38 MAPK
WB results were also consistent with Q-PCR data which indicated
similar levels of mRNA of p38 MAPK in WT-STZ, vehicle-
treated controls, and SOD2-STZ mice. The changes in the
phosphorylated levels of p38 MAPK can be ascribed to the
alteration of activation status of the kinase at 1-week of
hyperglycemia. Similarly, we observed increased phosphorylation
of tau at threonine-205 with no changes in tau protein or mRNA
levels. Our findings are in agreement with previous reports, [32]
where 3-day STZ-treatment causes activation of p38 MAPK in
conjunction with tau phosphorylation at threonine-205 in the
brains of mice. Additionally, Planel and coworkers, [33] reported
significant increase in tau phosphorylation at the threonine-205
site as early as 10 days post-STZ injection in mice brains.
Phosphorylation of tau protein at the threonine-205 and serine-
202 sites are early markers of tau dysfunction. In our study,
however, we did not observe a significant alteration of phosphor-
ylated levels of tau at serine-202 at the 1-week time point. (data not
shown). Because tau phosphorylation is believed to destabilize
microtubules and hinder fast axonal transport [34], our findings
indicate that the mechanism of axonal transport deficits observed
involves activation of p38 MAPK pathway in association with
phosphorylated tau protein due to acute hyperglycemia-induced
oxidative stress.
Current understanding regarding the short-term effects of
hyperglycemia is limited. Whereas, renal arterial and carotid
blood flow significantly drop and phosphorylated p38 MAPK and
ERK1/2 levels significantly increase in aorta and the cortex of the
kidney respectively by two weeks of STZ-induced diabetes [35],
little is known about the effects of acute hyperglycemia on
neurons. One can argue that the deficits in the axonal transport
observed in CNS neurons as early as 1 week could be due to STZ-
related toxicity. We ruled out the possibility of STZ-induced
toxicity by administering insulin for validation experiment (as
depicted in Figure 1) following STZ-treatment and observed
recovery in axonal transport rates. Thus, the deficits in axonal
transport rates that we observed are due to STZ-related insulin
deficiency and not toxicity. Additionally, our findings remained
consistent in a mouse model of glucose injection-induced
hyperglycemia that further confirmed that STZ-induced hyper-
glycemia was causing axonal transport deficits. However, it should
be also noted that it is not clear if similar beneficial effects of the
Figure 5. Phosphorylated Tau significantly increase in WT-STZ mice and recovers in SOD2-STZ mice, despite hyperglycemia.
Western blotting analysis of OB tissues from WT, WT-STZ, SOD2, SOD2-STZ mice show: (A) changes in site-specific phosphorylation of tau (p-tau) at
threonine 205, (seven mice in WT, WT-STZ groups and six in SOD2 and SOD2-STZ groups) (B) changes in total levels of tau protein, (seven mice in WT,
WT-STZ groups and six in SOD2 and SOD2-STZ groups) (C) QPCR of brain homogenates depict relative changes in mRNA levels of tau, (six mice used
in each of the four groups) and (D) representative western blot from OB homogenates from 1 week vehicle or STZ treated 2-4-month-old mice. The
results are normalized to b-actin. Statistical analysis: One way ANOVA followed by Dunnett’s post test. ** p,0.01, *p,0.05.
doi:10.1371/journal.pone.0013463.g005
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because the animal model we used is a transgenic animal that
overproduces the antioxidant SOD2 since birth. Clinical trials
involving antioxidant therapies to treat long-term diabetes-related
complications have resulted in controversial outcomes. Similar
controversial effects of antioxidant therapies have been observed in
other diseases as well (for e.g., Alzheimer’s disease). In such cases,
it has been proposed that factors such as the timing of
administration or the dosage may have affected the outcome of
the trials. Accordingly, if administered early enough (as early as 1
week hyperglycemia) we may be able to observe the beneficial
effects and prevention of nerve damage. Our results describe
restoration of axonal transport rates following SOD2 overexpres-
sion in animal models, and although the model we use does not
directly correlate with human disease, similar outcome may be
possible in diabetic patients, provided optimization of timing,
dosage and potency of antioxidant therapy used.
In conclusion, our results indicate that short-term hyperglyce-
mia-induced oxidative stress induces axonal transport deficits in
olfactory receptor neurons in conjunction with activation of
p38MAPK pathway and tau phosphorylation. Upon overexpres-
sion of SOD2, mitochondrial antioxidant enzyme, hyperglycemia-
induced oxidative stress-related axonal transport deficits recover.
Research efforts towards developing efficient tools to deliver
antioxidants or antioxidant precursors to the cells vulnerable to
hyperglycemia may prove valuable in combating hyperglycemia-
related complications.
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